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Structured summary 1 
Aims: Hyponatraemia is one of the major adverse effects of thiazide diuretics and the leading 2 
cause of drug-induced hyponatraemia requiring hospital admission. We sought to review and 3 
analyse all published cases of this important condition. 4 
Methods: Ovid Medline, Embase, Web of Science and PubMed electronic databases were 5 
searched to identify all relevant articles published before October 2013. A proportions meta-6 
analysis was undertaken. 7 
Results: 102 articles were identified of which 49 were single patient case reports. Meta-analysis 8 
showed that mean age was 75 (95% CI 73–77) years, 79% were women (95% CI 74–82) and 9 
mean body mass index was 25 (95% CI 20–30) kg/m2. Presentation with thiazide-induced 10 
hyponatraemia occurred a mean of 19 (95% CI 8-30) days after starting treatment, with mean 11 
trough serum sodium concentration of 116 (95% CI 113 to 120) mM and serum potassium of 3.3 12 
(95% CI 3.0 to 3.5) mM. Mean urinary sodium concentration was 64 mM (95% CI 47 to 81); the 13 
most frequently reported thiazides were hydrochlorothiazide, indapamide and 14 
bendroflumethiazide.  15 
Conclusions: Patients with thiazide-induced hyponatraemia were characterised by advanced age, 16 
female gender, inappropriate saliuresis and mild hypokalaemia. Low BMI was not found to be a 17 
significant risk factor, despite previous suggestions. The time from thiazide initiation to 18 
presentation with hyponatraemia suggests that the recommended practice of performing a single 19 
investigation of serum biochemistry 7–14 days after thiazide initiation may be insufficient or 20 
suboptimal. Further larger and more systematic studies of thiazide-induced hyponatraemia are 21 
required. 22 
 23 
 24 
 25 
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What is known about this subject 1 
• Thiazide/thiazide-like diuretics are amongst the top 5 most prescribed medicines in the UK and 2 
one of the most widely prescribed and effective anti-hypertensive classes of medication 3 
worldwide. 4 
• Most physicians are familiar with prescribing thiazides and of their limiting side effects, 5 
of which hyponatraemia is amongst the most commonly encountered and medically serious. 6 
• Thiazide-induced hyponatraemia is the leading cause of drug-induced hyponatremia 7 
requiring hospitalisation in the UK. 8 
What this study adds 9 
• This systematic review and meta-analysis is the first time (to our knowledge) that anyone 10 
has attempted to analyse the entire published literature (1962-2013) on this common and serious 11 
adverse drug effect. 12 
• This work challenges the perception that underweight patients are those who typically 13 
suffer from this side effect and, if people are sticking to the rules with serum electrolyte 14 
monitoring, calls into question whether the standard UK practise of a blood test 1-2 weeks after 15 
starting thiazides is optimal since the mean time to presentation with hyponatraemia occurred 16 
outside (after) this monitoring period. 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
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Introduction 1 
Thiazide and thiazide-like diuretics, although they differ in chemical structure, all inhibit the 2 
thiazide-sensitive sodium–chloride co-transporter, NCC, in the distal convoluted tubule of the 3 
kidney [1]. Since the demonstration of their anti-hypertensive effect in 1958 [2] they have been 4 
widely used in the management of hypertension, and continue to be so, notwithstanding their 5 
recent and controversial demotion to step 3 in UK hypertension guidance [3,4]. Their benefits on 6 
all-cause mortality are equal to those of angiotensin-converting enzyme (ACE) inhibitors and 7 
calcium channel antagonists [5,6].  8 
However thiazide diuretics often cause adverse effects, of which thiazide-induced 9 
hyponatraemia is amongst the most clinically important [7]. Thiazide-induced hyponatraemia 10 
may also represent a scientifically important paradigm of the dysregulation of sodium (and water) 11 
transport within the distal nephron [8].  12 
Thiazide diuretics are the most common cause of drug-induced hyponatraemia in 13 
secondary care [9]. Severe thiazide-induced hyponatraemia causes debilitating symptoms such as 14 
confusion, falls and seizures, and can sometimes be fatal [7]. Thiazide-induced hyponatraemia 15 
necessitating hospital admission is common enough to suggest that current monitoring regimens 16 
are suboptimal
 
[9]. Importantly, the mechanism of thiazide-induced hyponatraemia is also poorly 17 
understood; mean serum sodium concentration in the total treated population is virtually 18 
unchanged by thiazide therapy [10], implying that thiazide-induced hyponatraemia occurs in a 19 
susceptible subgroup. However this subgroup cannot be prospectively identified at present and 20 
so thiazide-induced hyponatraemia is largely unpredictable at the point of thiazide initiation.  We 21 
therefore set out to undertake a systematic review and meta-analysis of all thiazide-induced 22 
hyponatraemia reports published to date in order to summarise and reflect on current 23 
understanding of this condition.  24 
 25 
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Methods 1 
Search strategy 2 
Medline, Embase, Web of Science and PubMed databases were searched on 1
st
 October 2013 3 
without limitation on language. The Ovid interface was used to search Medline and Embase 4 
using the terms “thiazide AND hyponatr$emia”, “thiazide-induced hyponatr$emia” and 5 
“thiazide- associated hyponatr$emia”. Web of Science and PubMed were searched using the 6 
terms “(thiazide AND (hyponatraemia OR hyponatraemia)”, “(thiazide-induced AND 7 
(hyponatraemia OR hyponatraemia)”, “(thiazide-associated AND (hyponatraemia OR 8 
hyponatraemia)”.  Database searches were also undertaken with the term ‘thiazide’ replaced 9 
alternatively by either ‘indapamide’ or ‘chlortalidone’. Articles that cited or were cited by the 10 
included studies were also screened to identify any further relevant studies. Duplicated results 11 
and studies containing no primary data or non-human data only were removed. The conventional 12 
definition for hyponatraemia of serum sodium concentration ≤135mM was used [11,12]. 13 
Data extraction 14 
Two authors (JB and MG) independently reviewed the titles, abstracts and full text of identified 15 
papers. References of all full text papers were searched to identify any additional pertinent 16 
papers. Disagreements were resolved by discussion. Data extraction was performed using a 17 
structured template to collect information on study design (including location of study and year 18 
of publication) and thiazide-induced hyponatraemia phenotype including age, sex, presenting 19 
symptoms, drug history including concomitant drug use and laboratory findings. Methodological 20 
quality was independently rated by two authors (JB and MG) using a modified version scale 21 
developed for observational studies 
13
. The range of possible scores was 0-12. 22 
Data analysis 23 
Study parameters which were reported in more than 1% of patients are presented. We excluded 24 
from the analysis any measurement given qualitatively as “normal” without any indication of the 25 
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value itself or the reference range. For publications in which more than one patient was reported 1 
a proportions meta-analysis was conducted to look at the weighted frequency of clinical 2 
phenotype, drug history and laboratory findings for the combined number of papers contributing 3 
to each separate analysis. A random effects model was used to determine 95% confidence 4 
intervals, using the DerSimonian and Laird method to calculate weights [14]. Study 5 
heterogeneity was assessed using I
2
 scores. Causes of high levels of heterogeneity were explored 6 
by dividing the following variables at the median level: quality score, year of publication, and 7 
age of study population.  Evidence for the possibility of publication bias was assessed by funnel 8 
plots. Single case reports were simply summarised.   9 
The presentation of the meta-analyses adhered to the Meta-analysis of Observational 10 
Studies in Epidemiology (MOOSE) consensus statement [15]. All proportional analyses were 11 
performed using the Stats Direct

 statistical software package version 2.7.9 and Stata

 version 12 
12 for the meta-analyses of mean values.   13 
Results 14 
Database searches resulted in 1359 citations. After exclusion of duplicates and articles where 15 
data was non-human or irrelevant to thiazide-induced hyponatraemia in adults, 102 articles 16 
remained (median date of publication was 1998, range 1962-2013) and were analysed (Figure 1). 17 
Of the 102 articles analysed, 49 were single case reports [16-64] (Supplementary Table 1) and 18 
the remaining 52 articles ranged from 2 to 1802 patients [65-117] (Supplementary Table 2).  4 19 
papers were also removed because the same study population was already represented in the 102 20 
articles included in the review [118-121]. 21 
The mean value for quality score was 4.0 (range 1–8) for studies included in the meta-22 
analysis and 3.2 for single case reports (range 1–6). The main reasons for low quality scores 23 
were a lack of clearly stated inclusion and exclusion criteria, absence of documented patient 24 
consent and/or ethical approval, a lack of inclusion of patient perception, a lack of clarity 25 
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regarding the name, dose and duration of thiazide therapy and whether thiazide-induced 1 
hyponatraemia patients represented a consecutive series treated consistently by the same 2 
physician(s) or at a single institution.   3 
FIGURE 1 HERE 4 
Meta-analysis Findings 5 
Clinical Characteristics 6 
Patients with thiazide-induced hyponatraemia had a mean age of 75 years (pooled estimate, 95% 7 
CI 73 to 77 years, based on 36 studies and 2840 patients, Figure S1), 79% were women (95% CI 8 
74–82%, I2 = 65%, based on 43 studies and 3269 patients, Figure S2) and mean body mass index 9 
was 25 kg/m
2
 (pooled estimate, 95% CI 20–30 kg/m2, I2 = 100%, based on 2 studies and 2025 10 
patients, Figure S3). Thiazide-induced hyponatraemia was first detected a mean of 19 days 11 
(pooled estimate, 95% CI 8-30 days, I
2 
= 97%, based on 19 studies and 446 patients, Figure S4) 12 
after starting thiazide treatment (Table 1).  Sensitivity analysis by removal of studies with delay 13 
to thiazide-induced hyponataremia >100 days also showed the time to detection was greater than 14 
the standard 7-14 day serum electrolyte monitoring period (17 days, 95% CI 6 to 28 days, based 15 
on 14 studies with 415 patients). The levels of heterogeneity were explored by quality score, year 16 
of publication and age of patients; however none of these factors could explain the high levels of 17 
heterogeneity (Table S3).   18 
Clinical characteristics of patients with thiazide-induced hyponatraemia are presented in 19 
Table 2 (Meta-analyses graphs Figures S5 to S14). The most frequently reported symptoms at 20 
presentation were: falls (48%, 95% CI 20 to 77%, I
2 
= 84%, based on 5 studies and 252 patients); 21 
fatigue (46%, 95% CI 21 to 72%, I
2
= 92%, based on 8 studies and 333 patients); weakness (45%, 22 
95% CI 32 to 58%, I
2 
= 49%, based on 14 studies and 247 patients); confusion (44%, 95% CI 33 23 
to 56%, I
2 
= 85%, based on 22 studies and 710 patients); nausea (36%, 95% CI 24 to 48%, I
2 
= 24 
76%, based on 14 studies and 405 patients); and vomiting (35%, 95% CI 25 to 45%, I
2 
= 68%, 25 
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based on 13 studies and 549 patients). Also reported were other neurological symptoms, 1 
dizziness, unconsciousness and seizures (Table 2).  Analyses of clinical characteristics revealed 2 
substantial heterogeneity between studies which were not explained by quality score, year of 3 
publication or age of patient (Table S4). 4 
 5 
Co-morbidities 6 
The most commonly reported comorbidities included cardiovascular disease (49%, 95% 7 
CI 33 to 65%, I
2 
= 72%, based on 12 studies and 284 patients, Figures S15) and diabetes mellitus 8 
(27%, 95% CI 14 to 42%, I
2 
= 99%, based on 9 studies and 3029 patients, Figure S16).  Analyses 9 
of comorbidities revealed substantial heterogeneity between studies which was not explained by 10 
quality score, year of publication or age of patient (Table S3).   A single study of 1802 patients 11 
reported the prevalence of gastro-oesophageal reflux disease (24%), hyperlipidemia (47%) and 12 
urinary tract infection (24%) [104].  13 
 14 
Medication history 15 
Thiazide-induced hyponatraemia was reported in association with a wide range of 16 
thiazide/thiazide-like drugs (Table 3, meta-analyses graphs in Figures S17 to S22). By far the 17 
most frequently implicated was hydrochlorothiazide either alone (68%, 95% CI 52 to 82%, I
2 
= 18 
97%, based on 19 studies and 2583 patients) or in combination with amiloride (as Moduretic
®
, 19 
73%, 95% CI 57 to 87%, I
2 
= 92%, based on 19 studies and 633 patients) or triamterene (as 20 
Dyazide
®
, 18%, 95% CI 8 to 32%, I
2 
= 36%, based on 3 studies and 59 patients). Other 21 
thiazide/thiazide-like drugs implicated were indapamide, bendroflumethiazide (bendrofluazide), 22 
and chlortalidone. Analyses of which individual thiazide/thiazide-like drugs were associated with 23 
hyponatraemia revealed high levels of heterogeneity between studies and this was not explained 24 
by quality score, year of publication or age of patient (Table S4). 25 
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Details of concurrent non-thiazide medication in patients with thiazide-induced 1 
hyponatraemia are presented in Table 3 (meta-analyses graphs Figures S23 to S28). Commonly 2 
reported non-thiazide co-prescriptions were angiotensin II receptor antagonists (59%, 95% CI 0 3 
to 96%, I
2 
= 99%, based on 3 studies and 1844 patients), Angiotensin Converting Enzyme (ACE) 4 
inhibitors (51%, 95% CI 27 to 75%, I
2 
= 96%, based on 5 studies and 2000 patients), non-5 
thiazide diuretics (e.g. loop- and potassium sparing- diuretics) (58%, 95% CI 19 to 91%, I
2 
= 6 
86%, based on 5 studies and 1815 patients), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 7 
(33%, 95% CI 18 to 49%, I
2 
= 89%, based on 6 studies and 2036 patients), and anti-depressants 8 
(32%, 95% CI 19 to 47%, I
2 
= 68%, based on 6 studies and 1882 patients). While Selective 9 
Serotonin Reuptake Inhibitors (SSRIs) are associated with hyponatraemia, there was insufficient 10 
data to determine what proportion of the anti-depressant medication reported were SSRIs.  11 
Analyses of polypharmacy demonstrated high levels of heterogeneity between studies, which 12 
was not explained by quality score, year of publication or age of patient (Table S5). 13 
Laboratory Characteristics 14 
As shown in Table 4 (Figures S29 to S34), thiazide-induced hyponatraemia patients had severe 15 
hyponatraemia, with a mean trough serum sodium concentration of 116 mM (95% CI 113 to 120 16 
mM, I
2
=99%, based on 37 studies and 1042 patients), mild hypokalaemia, with serum potassium 17 
3.3 mM (95% CI 3.0 to 3.5 mM, I
2
=97%, based on 28 studies and 902 patients), and normal 18 
renal function, serum creatinine 76.8 µmol/L (95% CI 64.1 to 89.4 µmol/L, I
2
=99%, based on 17 19 
studies and 504 patients). Corresponding urinary electrolyte data indicates inappropriate 20 
saliuresis, with urinary sodium concentration 64 mM (95% CI 47 to 81 mM, I
2
=94%, based on 21 
13 studies and 98 patients). Mean serum and urine osmolalities were 240 mOsm/kg (95% CI 236 22 
to 245 mOsm/kg, I
2
=80%, based on 11 studies and 229 patients) and 402 mOsm/kg (95% CI 370 23 
to 432 mOsm/kg, I
2
=81%, based on 14 studies and 322 patients) respectively. In most analyses 24 
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of laboratory characteristics there were high levels of heterogeneity between studies, which were 1 
not explained by quality score, year of publication or age of patient (Table S6). 2 
Discussion 3 
We present, to our knowledge, the first systematic review and meta-analysis of the observational 4 
literature regarding the clinical and laboratory characteristics of thiazide-induced hyponatraemia. 5 
Patients with thiazide-induced hyponatraemia were characterised by advanced age, female 6 
gender, inappropriate saliuresis and mild hypokalaemia. In addition, patients had normal BMI, in 7 
contrast to suggestions that such patients tend to be underweight [7].  8 
The most notable finding is of the delay from thiazide initiation to diagnosis of thiazide-9 
induced hyponatraemia which averaged 19 days (95% CI 8 to 30 days, Figure S4).  Current best 10 
practice is to measure serum biochemistry 1–2 weeks after thiazide initiation [122]. Our data 11 
suggest that either best practice is not followed [123], or that testing at 1–2 weeks fails to detect 12 
some patients who go on to develop thiazide-induced hyponatraemia [9] in which case changes 13 
in monitoring schedules might improve current practice. Without data reporting either the 14 
frequency of routine biochemical monitoring or the levels of serum sodium from such 15 
monitoring it is not possible to confidently recommend what the optimal timing of a single 16 
electrolyte check should be or whether there would be merit in performing a second electrolyte 17 
measurement after the initial fortnight following thiazide initiation, e.g. at 3–4 weeks. Since in a 18 
few cases, severe hyponatraemia developed many months or even years after thiazide initiation, 19 
it would be prudent to measure serum electrolyte concentrations whenever patients treated with 20 
thiazides develop symptoms suggestive of hyponatraemia, regardless of the duration of thiazide 21 
therapy. 22 
Mild hypokalaemia accompanying thiazide-induced hyponatraemia may occur simply as 23 
a consequence of excessive saliuresis and consequent electrogenic exchange of potassium for 24 
sodium in the collecting duct. Additional mechanisms may also contribute; for example (1) 25 
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aldosterone activation of the distal nephron, as is to be expected and not uncommonly seen with 1 
thiazide-induced hypokalaemia and hyperaldosteronism [124], or (2) With No lysine protein 2 
Kinase (WNK) regulation of the renal outer-medullary potassium channel (ROMK) in the 3 
collecting duct and the thiazide-sensitive sodium chloride cotransporter (NCC) in the distal 4 
convoluted tubule as has been proposed for the hyperkalemia seen in Gordon syndrome [125], a 5 
Mendelian disorder of thiazide-responsive hypertension and metabolic acidosis. 6 
Hyperlipidemia was the most common comorbidity. Whilst severe hyperlipidemia is a 7 
well-recognised cause of pseudo-hyponatraemia in older studies that relied on methods such as 8 
flame photometry to measure serum sodium concentration, most dyslipidemia is very unlikely to 9 
affect modern assay methods. The second most common comorbidity was diabetes mellitus. 10 
Plasma glucose concentration was reported infrequently and it is possible that hyperglycemia 11 
could have contributed to hyponatraemia in some cases. Since for the vast majority of patients 12 
reported the indication for thiazide prescription was hypertension and presentation was with 13 
symptomatic hyponatraemia it is not possible to make meaningful conclusions either regarding 14 
thiazide-induced hyponatraemia when thiazide prescriptions were for indications other than 15 
hypertension or the differences between symptomatic versus non-symptomatic patients. 16 
Several of the medicines most commonly co-prescribed with thiazides among studies 17 
included in this meta-analysis, such as ACE inhibitors, AT1 receptor antagonists, NSAIDS and 18 
some anti-depressants, are associated with hyponatraemia through well-described mechanisms. 19 
This raises the possibility that some cases of apparent thiazide-induced hyponatraemia could 20 
result from pharmacodynamic interactions of these drugs with thiazides. It was also notable that 21 
hypokalaemia was seen despite the frequency of concurrent therapy with ACE inhibitors, AT1 22 
receptor antagonists and potassium supplements. 23 
 The finding of a normal serum creatinine concentration is unexpected in such an elderly 24 
cohort at higher than average vascular risk, many of whom also took ACE inhibitors, ARBs 25 
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and/or NSAIDs. BMI was normal, so low muscle mass is unlikely to predominantly account for 1 
this raising the possibility of a dilutional component to the observed serum creatinine 2 
concentrations. Thus in addition to inappropriate saliuresis and inappropriately high urinary 3 
osmolarity, inappropriately low serum creatinine concentration is consistent with volume 4 
expansion and the overall phenotype could therefore be alternatively described as having much 5 
in common with  thiazide-induced Syndrome of Inappropriate Anti-Diuretic Hormone secretion 6 
(SIADH) [126].   7 
There are significant limitations to this systematic review. Included studies were very 8 
heterogenous with respect to the detail of their description, specific parameters recorded and 9 
laboratory methods used and this did not appear to be explained by either individual study 10 
quality, median date of publication, or whether the study pertained to a particular ‘specialist 11 
group’. One possible explanation for the high level of heterogeneity found in the analyses may 12 
be the local prescribing habits of the areas in which these often small studies were undertaken 13 
given that case series usually focused on small numbers from a single institution over a relatively 14 
short project interval. Case reports were excluded from our meta-analysis but we accept that a 15 
case report may describe unusual but important presenting clinical and laboratory characteristics 16 
of patients with thiazide-induced hyponatraemia. For this reason we have presented a summary 17 
of the case report data alongside that for the meta-analysis in Tables 1-4. It is also possible that 18 
some publications were not identified by our search of the four principal databases used, 19 
however the extensive searches and the searching of references list limits the possibility of many 20 
missing articles.  Publication bias is still a possibility; however none of the funnel plots from the 21 
meta-analyses indicated that this was a problem.  The vast majority of reports detailed patients 22 
who had been admitted to hospitals with symptomatic hyponatraemia and it is therefore likely 23 
that asymptomatic and non-hospitalised patients with thiazide-induced hyponatraemia are 24 
underrepresented. 25 
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There are also specific issues with respect to the phenotypic parameters measured by 1 
observational studies; advanced age is confounded by the prescribing of thiazides to older 2 
patients and the over-representation of females may be confounded by the shorter life expectancy 3 
of males. Although oestrogens do affect sodium transport via the thiazide-sensitive NCC [127], 4 
the age of the cohort reported would put the vast majority well beyond the menopause. 5 
Alternatively perhaps the sex distribution is pathophysiologically significant; in the age category 6 
70–74 years for the UK in the median year of publication (1998), females constituted only 55% 7 
of the population [128] and yet 73% of thiazide-induced hyponatraemia patients in our meta-8 
analysis were female. 9 
It is not possible to draw meaningful conclusions regarding the prevalence of thiazide-10 
induced hyponatraemia with respect to individual thiazide drugs from the available data, apart 11 
from observing that thiazide-induced hyponatraemia is reported with many thiazides including 12 
indapamide and chlortalidone, the two currently recommended thiazide-like diuretics for 13 
hypertension in the UK [4]. 14 
The detailed study of the phenotype and pathophysiology of patients with thiazide-15 
induced hyponatraemia has the potential not only to improve clinical care of patients prescribed 16 
thiazides but also potentially to uncover novel pathophysiological insights into salt and water 17 
handling in the kidney which are clearly disturbed in these individuals. In the absence of a 18 
prospective trial exposing thousands of patients to thiazides with extensive follow up (which is 19 
unlikely due to prohibitive expense and limited interest from pharmaceutical companies given 20 
the very old non-patented nature of thiazides), larger scale prospective observational studies with 21 
detailed phenotyping of thiazide-induced hyponatraemia patients is required. Such a study is 22 
already taking place across several acute hospitals throughout the UK (NIHR CRN portfolio 23 
identity 10795).  24 
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In conclusion this study found that patients with thiazide-induced hyponatraemia were 1 
characterised by advanced age, female gender, inappropriate saliuresis and mild hypokalaemia. 2 
Such patients had a normal BMI and were diagnosed later than the usual serum electrolyte 3 
monitoring interval of 7-14 days after thiazide commencement. Until further studies determine 4 
the optimal timing and frequency of electrolyte monitoring regimens it would seem prudent to be 5 
mindful of the development of hyponatraemia outside of the first fortnight of thiazide therapy. 6 
 7 
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Figures 11 
Figure 1: Flow diagram of steps in systematic review in PRISMA format.  12 
Tables 13 
Table 1: Analysis of pooled data of the age, gender, BMI and duration of thiazide therapy of 14 
patients with thiazide-induced hyponatraemia.  15 
Body Mass Index (BMI), TIH (Thiazide Induced Hyponatraemia), Confidence Interval (CI), Pop 16 
(Contributing population to the meta-analyses, number of studies/total number of patients with 17 
the studies), Standard deviation (SD) and N (number of patients in single case reports). * Data 18 
expressed as proportion 19 
 20 
Table 2: Meta-analysis of the symptoms reported at presentation in patients with thiazide-21 
induced hyponatraemia.  22 
Prevalence estimates from meta-analysis and confidence intervals are all expressed as 23 
proportions. Prop (proportion), Pop (Contributing population to the meta-analyses, number of 24 
27 
 
studies/total number of patients with the studies), Confidence Interval (CI), N (number of single 1 
case reports reporting the variable listed). 2 
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Table 3: Meta-analysis of the drug history in patients with thiazide-induced hyponatraemia.  4 
Prevalence estimates from meta-analysis and confidence intervals are all expressed as 5 
proportions of those studies that reported each given variable at least once. 6 
HydroChloroThiaZide (HCTZ), AngioTensin Converting enzyme (ACE) inhibitor, Non-7 
Steroidal AntiInflammatory Drug (NSAID), Angiotensin Receptor Blocker (ARB),  Prop 8 
(proportion), Pop (Contributing population to the meta-analyses, number of studies/total number 9 
of patients with the studies), Confidence Interval (CI), N (number of single case reports reporting 10 
the variable listed).  11 
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Table 4: Meta-analysis of laboratory characteristics in patients with thiazide-induced 13 
hyponatraemia.  14 
Prevalence estimates from meta-analysis and confidence intervals are all expressed as 15 
proportions. Confidence Interval (CI), N (number of single case reports reporting the variable 16 
listed), Standard deviation (SD). 17 
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